Ibrutinib in Refractory or Relapsing Primary Central Nervous System Lymphoma: A Systematic Review
Primary Central Nervous System Lymphoma (PCNSL) is a rare variant of Non-Hodgkin Lymphoma (NHL) representing 1–2% of all NHL cases. PCNSL is defined as a lymphoma that occurs in the brain, spinal cord, leptomeninges, or eyes. Efforts to treat PCNSL by traditional chemotherapy and radiotherapy have g...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-01-01
|
| Series: | Neurology International |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2035-8377/14/1/9 |
| _version_ | 1797444085759344640 |
|---|---|
| author | Gaurav Nepal Mahika Khurana Domenica Herrera Bucheli Siddhartha Bhandari Utsav Joshi Riwaj Bhagat Jessica Holly Rehrig Prasun Pudasainee Yow Ka Shing Juan Fernando Ortiz Rajeev Ojha Bikram Prasad Gajurel Jonathan Quinonez Samir Ruxmohan Trevine Albert Steven Licata Joel Stien |
| author_facet | Gaurav Nepal Mahika Khurana Domenica Herrera Bucheli Siddhartha Bhandari Utsav Joshi Riwaj Bhagat Jessica Holly Rehrig Prasun Pudasainee Yow Ka Shing Juan Fernando Ortiz Rajeev Ojha Bikram Prasad Gajurel Jonathan Quinonez Samir Ruxmohan Trevine Albert Steven Licata Joel Stien |
| author_sort | Gaurav Nepal |
| collection | DOAJ |
| description | Primary Central Nervous System Lymphoma (PCNSL) is a rare variant of Non-Hodgkin Lymphoma (NHL) representing 1–2% of all NHL cases. PCNSL is defined as a lymphoma that occurs in the brain, spinal cord, leptomeninges, or eyes. Efforts to treat PCNSL by traditional chemotherapy and radiotherapy have generally been unsuccessful as a significant proportion of patients have frequent relapses or are refractory to treatment. The prognosis of patients with Refractory or Relapsed (R/R) PCNSL is abysmal. The optimal treatment for R/R PCNSL is poorly defined as there are only a limited number of studies in this setting. Several studies have recently shown that ibrutinib, a Bruton tyrosine kinase (BTK) inhibitor, has promising results in the treatment of R/R PCNSL. However, these are preliminary studies with a limited sample size. In this systematic review, we explored and critically appraised the evidence about the efficacy of the novel agent ibrutinib in treating R/R PCNSL. |
| first_indexed | 2024-03-09T13:06:30Z |
| format | Article |
| id | doaj.art-47ef347b78db4bdc988035daef4bcf49 |
| institution | Directory Open Access Journal |
| issn | 2035-8377 |
| language | English |
| last_indexed | 2024-03-09T13:06:30Z |
| publishDate | 2022-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Neurology International |
| spelling | doaj.art-47ef347b78db4bdc988035daef4bcf492023-11-30T21:47:33ZengMDPI AGNeurology International2035-83772022-01-011419910810.3390/neurolint14010009Ibrutinib in Refractory or Relapsing Primary Central Nervous System Lymphoma: A Systematic ReviewGaurav Nepal0Mahika Khurana1Domenica Herrera Bucheli2Siddhartha Bhandari3Utsav Joshi4Riwaj Bhagat5Jessica Holly Rehrig6Prasun Pudasainee7Yow Ka Shing8Juan Fernando Ortiz9Rajeev Ojha10Bikram Prasad Gajurel11Jonathan Quinonez12Samir Ruxmohan13Trevine Albert14Steven Licata15Joel Stien16Department of Internal Medicine, Tribhuvan University Institute of Medicine, Maharajgunj, Kathmandu 44600, NepalDepartment of Public Health, Berkeley Public Health Division, Berkeley, CA 94704, USADepartment of Medicine, Universidad Internacional de Ecuador, Loja 110150, EcuadorDepartment of Internal Medicine, Tribhuvan University Institute of Medicine, Maharajgunj, Kathmandu 44600, NepalDepartment of Internal Medicine, Rochester General Hospital, Rochester, NY 14621, USADepartment of Neurology, Boston University Medical Center, Boston, MA 02118, USADepartment of Neurology, North Shore University Hospital, Manhasset, NY 11030, USADepartment of Internal Medicine, AMITA Health Saint Francis Hospital, Evanston, IL 60202, USADepartment of Internal Medicine, National University Hospital, Singapore 119074, SingaporeDepartment of Neurology, California Institute of Behavioral Neuroscience & Psychology, Fairfield, CA 94534, USADepartment of Neurology, Tribhuvan University Teaching Hospital, Kathmandu 44600, NepalDepartment of Neurology, Tribhuvan University Teaching Hospital, Kathmandu 44600, NepalDepartment of Neurology, Larkin Community Hospital, South Miami, FL 100181, USADepartment of Neurology, Larkin Community Hospital, South Miami, FL 100181, USADepartment of Osteopathic Neuromuscular Medicine, Larkin Community Hospital, Miami, FL 100181, USADepartment of Osteopathic Neuromuscular Medicine, Larkin Community Hospital, Miami, FL 100181, USADepartment of Osteopathic Neuromuscular Medicine, Larkin Community Hospital, Miami, FL 100181, USAPrimary Central Nervous System Lymphoma (PCNSL) is a rare variant of Non-Hodgkin Lymphoma (NHL) representing 1–2% of all NHL cases. PCNSL is defined as a lymphoma that occurs in the brain, spinal cord, leptomeninges, or eyes. Efforts to treat PCNSL by traditional chemotherapy and radiotherapy have generally been unsuccessful as a significant proportion of patients have frequent relapses or are refractory to treatment. The prognosis of patients with Refractory or Relapsed (R/R) PCNSL is abysmal. The optimal treatment for R/R PCNSL is poorly defined as there are only a limited number of studies in this setting. Several studies have recently shown that ibrutinib, a Bruton tyrosine kinase (BTK) inhibitor, has promising results in the treatment of R/R PCNSL. However, these are preliminary studies with a limited sample size. In this systematic review, we explored and critically appraised the evidence about the efficacy of the novel agent ibrutinib in treating R/R PCNSL.https://www.mdpi.com/2035-8377/14/1/9ibrutinibBTKBruton tyrosine kinase inhibitorPCNSLprimary central nervous system lymphomalymphoma |
| spellingShingle | Gaurav Nepal Mahika Khurana Domenica Herrera Bucheli Siddhartha Bhandari Utsav Joshi Riwaj Bhagat Jessica Holly Rehrig Prasun Pudasainee Yow Ka Shing Juan Fernando Ortiz Rajeev Ojha Bikram Prasad Gajurel Jonathan Quinonez Samir Ruxmohan Trevine Albert Steven Licata Joel Stien Ibrutinib in Refractory or Relapsing Primary Central Nervous System Lymphoma: A Systematic Review Neurology International ibrutinib BTK Bruton tyrosine kinase inhibitor PCNSL primary central nervous system lymphoma lymphoma |
| title | Ibrutinib in Refractory or Relapsing Primary Central Nervous System Lymphoma: A Systematic Review |
| title_full | Ibrutinib in Refractory or Relapsing Primary Central Nervous System Lymphoma: A Systematic Review |
| title_fullStr | Ibrutinib in Refractory or Relapsing Primary Central Nervous System Lymphoma: A Systematic Review |
| title_full_unstemmed | Ibrutinib in Refractory or Relapsing Primary Central Nervous System Lymphoma: A Systematic Review |
| title_short | Ibrutinib in Refractory or Relapsing Primary Central Nervous System Lymphoma: A Systematic Review |
| title_sort | ibrutinib in refractory or relapsing primary central nervous system lymphoma a systematic review |
| topic | ibrutinib BTK Bruton tyrosine kinase inhibitor PCNSL primary central nervous system lymphoma lymphoma |
| url | https://www.mdpi.com/2035-8377/14/1/9 |
| work_keys_str_mv | AT gauravnepal ibrutinibinrefractoryorrelapsingprimarycentralnervoussystemlymphomaasystematicreview AT mahikakhurana ibrutinibinrefractoryorrelapsingprimarycentralnervoussystemlymphomaasystematicreview AT domenicaherrerabucheli ibrutinibinrefractoryorrelapsingprimarycentralnervoussystemlymphomaasystematicreview AT siddharthabhandari ibrutinibinrefractoryorrelapsingprimarycentralnervoussystemlymphomaasystematicreview AT utsavjoshi ibrutinibinrefractoryorrelapsingprimarycentralnervoussystemlymphomaasystematicreview AT riwajbhagat ibrutinibinrefractoryorrelapsingprimarycentralnervoussystemlymphomaasystematicreview AT jessicahollyrehrig ibrutinibinrefractoryorrelapsingprimarycentralnervoussystemlymphomaasystematicreview AT prasunpudasainee ibrutinibinrefractoryorrelapsingprimarycentralnervoussystemlymphomaasystematicreview AT yowkashing ibrutinibinrefractoryorrelapsingprimarycentralnervoussystemlymphomaasystematicreview AT juanfernandoortiz ibrutinibinrefractoryorrelapsingprimarycentralnervoussystemlymphomaasystematicreview AT rajeevojha ibrutinibinrefractoryorrelapsingprimarycentralnervoussystemlymphomaasystematicreview AT bikramprasadgajurel ibrutinibinrefractoryorrelapsingprimarycentralnervoussystemlymphomaasystematicreview AT jonathanquinonez ibrutinibinrefractoryorrelapsingprimarycentralnervoussystemlymphomaasystematicreview AT samirruxmohan ibrutinibinrefractoryorrelapsingprimarycentralnervoussystemlymphomaasystematicreview AT trevinealbert ibrutinibinrefractoryorrelapsingprimarycentralnervoussystemlymphomaasystematicreview AT stevenlicata ibrutinibinrefractoryorrelapsingprimarycentralnervoussystemlymphomaasystematicreview AT joelstien ibrutinibinrefractoryorrelapsingprimarycentralnervoussystemlymphomaasystematicreview |